Heijman Jordi, Voigt Niels, Dobrev Dobromir
Institute of Pharmacology, Medical Faculty Essen, University of Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany.
Future Cardiol. 2013 Jan;9(1):71-88. doi: 10.2217/fca.12.78.
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and has a significant impact on morbidity and mortality. Current antiarrhythmic drugs for AF suffer from limited safety and efficacy, probably because they were not designed based on specific pathological mechanisms. Recent research has provided important insights into the mechanisms contributing to AF and highlighted several potential novel antiarrhythmic strategies. In this review, we highlight the main pathological mechanisms of AF, discuss traditional and novel aspects of atrial antiarrhythmic drugs in relation to these pathological mechanisms, and present potential novel therapeutic approaches including structure-based modulation of atrial-specific cardiac ion channels, restoring abnormal Ca(2+) handling in AF and targeting atrial remodeling.
心房颤动（AF）是最常见的心律失常，对发病率和死亡率有重大影响。目前用于治疗AF的抗心律失常药物存在安全性和有效性有限的问题，这可能是因为它们并非基于特定的病理机制设计。最近的研究为AF的发病机制提供了重要见解，并突出了几种潜在的新型抗心律失常策略。在本综述中，我们重点介绍AF的主要病理机制，讨论心房抗心律失常药物与这些病理机制相关的传统和新方面，并介绍潜在的新型治疗方法，包括基于结构调节心房特异性心脏离子通道、恢复AF中异常的Ca(2+)处理以及针对心房重构。
